Ranbaxy AIDS Drugs Suspended From U.S. Program
This article was originally published in PharmAsia News
The President's Emergency Plan for AIDS Relief has suspended funding for three Ranbaxy generic drugs, in the wake of U.S. FDA issuing an import alert and two warning letters citing GMP deficiencies at Ranbaxy plants in Paonta Sahib and Dewas, India. The three HIV drugs - zidovudine, lamivudine and nevirapine - are manufactured at the Panota Sahib plant. The U.S. program, which supplies medicines to developing countries, paid $8.9 million for Ranbaxy AIDS drugs last fiscal year. (Click here for more
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.